| 職務内容 |
当ユニットでは、有効な制御法が未確立な難治性ウイルス感染症および世界的な流行拡大が懸念される重点感染症を対象に、病原体特性と免疫応答の解明に基づく革新的な予防・治療戦略の構築を推進し、早期の社会実装による医療および公衆衛生への貢献を目指しています。
現在、東京都特別研究「新型コロナウイルス等予防ワクチンの開発研究の推進」として、高い広域交差性と長期の免疫持続効果を併せ持つ、新規COVID-19ワクチンおよび汎用型コロナウイルス感染症ワクチンの開発を進めています。ワクシニアウイルスベクターを用いた組換えワクチンの作製に加え、広域反応性を発揮できるワクチン抗原設計や、粘膜免疫誘導を含む接種法の検討も行っています。さらに、開発したワクチン候補の有効性を感染動物モデルで検証し、GMPワクチン製剤の開発への展開を目指しています。重症急性呼吸器感染症対策と新規ワクチン開発に熱意を持って取り組む研究員及び技術員を公募いたします。
詳細は下記ウェブサイトを参照してください。
こちら感染制御ユニット
- Shobayashi K, Park J, Aoyagi H, Yasui F, Kohara M, Kim B. Precision dosing of recombinant vaccinia vaccine via pillar-guided microneedle patch confers SARS-CoV-2 immunity. Sci Rep. 2025 Dec 29;15(1):44894. doi: 10.1038/s41598-025-29183-z. PMID: 41461806.
- Nguyen CT, Nakayama M, Yasui F, Ishigaki H, Otaki K, Yamamoto N, Sanada T, Yamaji K, Honda T, Matsumoto Y, Kitagawa N, Ishii K, Kusayanagi T, Yagi Y, Kohara M, Itoh Y. Vaccinia virus-based SARS-CoV-2 vaccine prevents lung immunopathology without antibody-dependent enhancement in female rhesus macaques. Virology. 2025 Dec 18;616:110778. doi: 10.1016/j.virol.2025.110778. Online ahead of print. PMID: 41429087
- Kobiyama K, Utsumi D, Kaku Y, Sasaki E, Yasui F, Okamura T, Onodera T, Tobuse AJ, Sakkour A, Amiry AF, Hayashi T, Temizoz B, Liu K, Negishi H, Toyama-Sorimachi N, Kohara M, Sawasaki T, Takagi J, Sato K, Takahashi Y, Yasutomi Y, Ishii KJ. Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox. EBioMedicine. 2025 May;115:105703. doi: 10.1016/j.ebiom.2025.105703. Epub 2025 Apr 15. PMID: 40239465.
- Yasui F, Munekata K, Fujiyuki T, Kuraishi T, Yamaji K, Honda T, Gomi S, Yoneda M, Sanada T, Ishii K, Sakoda Y, Kida H, Hattori S, Kai C, Kohara M. Single Dose of Attenuated Vaccinia Viruses Expressing H5 Hemagglutinin Affords Rapid and Long-Term Protection Against Lethal Infection with Highly Pathogenic Avian Influenza A H5N1 Virus in Mice and Monkeys. Vaccines (Basel). 2025 Jan 15;13(1):74. doi: 10.3390/vaccines13010074. PMID: 39852853.
- Matsumoto Y, Honda T, Yasui F, Endo A, Takagi A, Kono R, Yamaji K, Yamamoto N, Saeki Y, Kohara M. Generation of a SARS-CoV-2-susceptible mouse model using adenovirus vector expressing human angiotensin-converting enzyme 2 driven by an elongation factor 1α promoter with leftward orientation. Front. Immunol. 2024 Dec 9;15:1440314. doi: 10.3389/fimmu.2024.1440314. eCollection 2024. PMID: 39717778.
- Sanada T, Honda T, Kohara M. Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination. Vaccine. 2024 Aug 30;42(21):126146.
- Abbasi S, Matsui-Masai M, Yasui F, Hayashi A, Tockary TA, Mochida Y, Akinaga S, Kohara M, Kataoka K, Uchida S. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol Ther. 2024 May 1;32(5):1266-1283.
- Otsubo N, Fukuda T, Beppu H, Maki C, Yasui F, Hanawa T, Sugita C, Murakami M, Yamada T, Kohara M, Wakai S. Reduced antibody response to SARS-CoV-2 in COVID-19 patients with newly diagnosed diabetes: a retrospective observational study. BMC Endocr Disord. 2023 Jan 6;23(1):5.
- Sanada T, Honda T, Higa M, Yamaji K, Yasui F, Kohara M. Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan. J Infect Chemother. 2023 Mar;29(3):339-346. †Co-first authors
- Ishigaki H, Yasui F, Nakayama M, Endo A, Yamamoto N, Yamaji K, Nguyen CT, Kitagawa Y, Sanada T, Honda T, Munakata T, Higa M, Toyama S, Kono R, Takagi A, Matsumoto Y, Koseki A, Hayashi K, Shinohara M, Ishii K, Saeki Y, Itoh Y, Kohara M. An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants. Front Microbiol. 2022 Nov 18;13:967019.
- Toya T, Atsuta Y, Sanada T, Honda T, Sadato D, Sekiya N, Kogure H, Takakuwa S, Onai D, Shingai N, Shimizu H, Najima Y, Kobayashi T, Ohashi K, Harada Y, Kohara M, Doki N. Attenuated humoral response against SARS-CoV-2 mRNA vaccination in allogeneic stem cell transplantation recipients. Cancer Sci. 2022 Sep 26:10.1111/cas.15603.
- Sanada T, Kohara M. Response to the Letter to the Editor regarding "Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021". J Epidemiol. 2022 Jul 30.
- Yasui F, Matsumoto Y, Yamamoto N, Sanada T, Honda T, Munakata T, Itoh Y, Kohara M. Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Sci Rep. 2022;12(1):4150.
- Beppu H, Fukuda T, Kawanishi T, Yasui F, Toda M, Kimura H, Nakamura Y, Nakamura Y, Kojima K, Ogawa H, Ishiwatari A, Kamei Y, Ogawa T, Abe Y, Endo M, Hanawa T, Mizobuchi R, Sugita C, Okamoto K, Hatakeyama S, Yamada T, Kohara M, Wakai S. Hemadialysis patients with coronavirus disease 2019: reduced antibody response. Clin Exp Nephrol. 2022; 26(2): 170-177.
- Sanada T, Honda T, Yasui F, Yamaji K, Munakata T, Yamamoto N, Kurano M, Matsumoto Y, Kohno R, Toyama S, Kishi Y, Horibe T, Kaneko Y, Kakegawa M, Fukui K, Kawamura T, Daming W, Qian C, Xia F, He F, Yamasaki S, Nishida A, Harada T, Higa M, Tokunaga Y, Takagi A, Itokawa M, Kodama T, Kohara M. Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021. J Epidemiol. 2021 Nov 13.
|
（Excel）
（PDF）